May 8, 2023 11:17 AM EDT

CRISPR unicorn Mammoth backs off diagnostics research, laying off 35 on testing team to focus on therapeutics

Andrew Dunn

Senior Biopharma Correspondent

Mammoth Biosciences is taking a big step away from its original ambition of upending the diagnostics business with CRISPR, and has laid off the bulk …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

CRISPR unicorn Mammoth backs off diagnostics research, laying off 35 on testing team to focus on therapeutics

Andrew Dunn

Senior Biopharma Correspondent

Sign up to read this article for free.

COO / Head of Operations (Stealth Portfolio Company)‬ ‭

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Big leases, bigger regrets: Biotech slump turns swanky offices from asset into liability

Altos Labs buys anti-aging startup Dorian Therapeutics

Genentech expands deal with molecular glue biotech Orionis for $105M upfront

Cocaine vaccine, a longshot attempt to quell cravings, yields mixed data in small study

Updated: Trump administration reveals 'most favored nation' drug price country targets

Does your supply chain hold up under pressure for high-risk temperature-critical shipments?

CRISPR uni­corn Mam­moth backs off di­ag­nos­tics re­search, lay­ing off 35 on test­ing team to fo­cus on ther­a­peu­tics

Senior Biopharma Correspondent

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

CRISPR unicorn Mammoth backs off diagnostics research, laying off 35 on testing team to focus on therapeutics